Welcome to our dedicated page for Fusion Pharmaceuticals Common Shares news (Ticker: FUSN), a resource for investors and traders seeking the latest updates and insights on Fusion Pharmaceuticals Common Shares stock.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) is a clinical-stage oncology company based in Hamilton, Ontario, Canada, and Boston, focusing on the development of next-generation radioconjugates (RCs) for precision cancer treatments. The company specializes in targeted alpha therapy (TAT), leveraging their unique expertise in linking alpha particle-emitting isotopes to targeting molecules to create highly effective therapeutics.
Fusion’s lead program, FPI-2265, is designed specifically for metastatic castration-resistant prostate cancer (mCRPC). This innovative treatment targets the prostate-specific membrane antigen (PSMA) and is currently undergoing a Phase 2 clinical trial. FPI-2265 aims to improve patient outcomes by delivering a potent radioactive payload directly to cancer cells, minimizing damage to healthy tissues. The recent Phase 2 TATCIST trial results, presented at the AACR Annual Meeting 2024, demonstrated promising clinical activity and safety, with meaningful improvements in secondary endpoints for mCRPC patients.
Fusion’s pipeline includes several other promising candidates, such as FPI-1434, targeting the insulin growth factor 1 receptor (IGF1R), FPI-2059, targeting the neurotensin receptor 1 (NTSR1), and FPI-2068, a bispecific IgG-based RC targeting EGFR-cMET.
The recent acquisition of Fusion by AstraZeneca marks a significant milestone. AstraZeneca will acquire all of Fusion’s outstanding shares for $21.00 per share in cash, plus a non-transferable contingent value right of $3.00 per share, subject to achieving specific regulatory milestones. This acquisition, valued at approximately $2.4 billion, underscores Fusion's pivotal role in pioneering RCs and enhancing AstraZeneca's oncology portfolio.
Fusion operates a state-of-the-art Good Manufacturing Practice (GMP) compliant facility, ensuring the production of clinical doses for its expanding pipeline. The company has strategic actinium supply agreements with Niowave, Inc., and BWXT Medical to meet the growing demand for their therapies.
With a robust pipeline, strategic partnerships, and a strong balance sheet, Fusion is well-positioned to advance their mission of transforming cancer treatment through innovative alpha-emitting radioconjugates.
Fusion Pharmaceuticals (FUSN) announced the nomination of its first targeted alpha therapy (TAT) candidate in collaboration with AstraZeneca (AZN). This candidate utilizes Fusion's Fast-Clear™ linker technology and involves an actinium-225 radiolabeled bispecific antibody. The Phase 1 study is set to proceed following IND-enabling studies, with both companies sharing development costs. Fusion is also advancing its lead program, FPI-1434, targeting IGF-1R in Phase 1 trials, and has a pipeline that includes FPI-1966 and FPI-2059. The collaboration aims to explore up to three TATs and five combination therapies.
Fusion Pharmaceuticals (Nasdaq: FUSN) announces its presentation at the 2021 Jefferies London Healthcare Conference on November 18, 2021, at 8:00 am GMT. Chief Executive Officer John Valliant, Ph.D. will represent the company. A recording will be available for on-demand viewing post-event.
The company develops next-generation radiopharmaceuticals, including its lead program FPI-1434, currently in Phase 1 clinical trials. Fusion also collaborates with AstraZeneca and Merck to advance its innovative therapies.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) reported its Q3 2021 financial results, highlighting a net loss of $19.4 million, or $0.45 per share, an increase from $10.0 million in Q3 2020. The company faces delays in patient enrollment for FPI-1434 due to the COVID-19 pandemic, now expecting multi-dose data in 2H 2022. The Phase 1 study of FPI-1966 has begun, with initial patient dosing anticipated in Q1 2022. Fusion holds $238.2 million in cash and investments, sufficient to fund operations through 2023.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announced a stock option grant of 90,400 shares to a new employee, per Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $7.09, equal to the stock's closing price on November 1, 2021. Vesting occurs over four years, starting with 25% after one year. Fusion focuses on developing next-generation radiopharmaceuticals as precision medicines, with its lead program, FPI-1434, in Phase 1 trials. The company also collaborates with AstraZeneca and Merck on innovative cancer treatments.
Fusion Pharmaceuticals has appointed Christopher Leamon, Ph.D., as the new Chief Scientific Officer. With over 25 years of experience in developing radiopharmaceuticals, Leamon's expertise is expected to enhance Fusion's R&D capabilities. Eric Burak, Ph.D., who served as Chief Scientific Officer, now takes on the role of Chief Technology Officer. The company is advancing its pipeline, including the IND-approved FPI-1434 and two additional projects. Leamon received a stock option grant of 218,000 shares at $7.09 each, reflecting his integral position in the company.
Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) announced promising preclinical results for its targeted alpha therapies (TATs), FPI-1966 and FPI-2059, presented at the 34th Annual EANM Congress. FPI-1966 showed therapeutic efficacy in bladder cancer models, while FPI-2059 outperformed a beta-emitting competitor in colorectal cancer studies. The company plans to initiate a Phase 1 study for FPI-1966 by year-end 2021 and submit an IND for FPI-2059 in early 2022, enhancing its portfolio aimed at solid tumors with high unmet medical needs.
Fusion Pharmaceuticals announced the appointment of Mohit Rawat as President and Chief Business Officer. Rawat brings over 15 years of biopharmaceutical experience, notably from Novartis, where he contributed to significant product launches. The company is positioned for growth, with plans to advance its pipeline of radiopharmaceuticals, including a third program expected in clinical trials by mid-2022. Rawat's expertise in corporate strategy and business development is expected to enhance Fusion's efforts in creating targeted alpha therapies and establishing global partnerships.
Fusion Pharmaceuticals (Nasdaq: FUSN) will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on September 29, 2021, at 2:40 PM ET, with CEO John Valliant, Ph.D. The presentation will be available via a live webcast on the Company's website, and a replay will be archived for 90 days after the event. Fusion is focused on developing next-generation radiopharmaceuticals, including its lead program FPI-1434 in a Phase 1 trial. The company has collaborations with AstraZeneca and Merck to enhance its innovative pipeline.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announced the appointment of Eric S. Hoffman, Ph.D. as senior vice president of business development on September 21, 2021. Dr. Hoffman brings over 15 years of experience in biotechnology, having previously led business development at Vicarius Pharma and Genocea Biosciences. His appointment aims to support Fusion's growing pipeline of targeted alpha therapies (TATs). Fusion is advancing several promising programs, including FPI-1434, currently in Phase 1 trials, and establishing partnerships with AstraZeneca and Merck for further development.
Fusion Pharmaceuticals (Nasdaq: FUSN) announced its participation in two virtual investor conferences. The company will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 11:00 AM ET, with CEO John Valliant and CFO John Crowley. A recording of the presentation at the H.C. Wainwright 23rd Annual Global Investment Conference will be available on September 13, 2021, at 7:00 AM ET. Webcasts will be accessible on the company's website, with replays archived for 90 days.
Fusion specializes in developing next-generation radiopharmaceuticals for oncology.
FAQ
What is the current stock price of Fusion Pharmaceuticals Common Shares (FUSN)?
What is the market cap of Fusion Pharmaceuticals Common Shares (FUSN)?
What does Fusion Pharmaceuticals Inc. specialize in?
What is Fusion's lead program?
What recent achievement has Fusion Pharmaceuticals accomplished?
What is the significance of the acquisition by AstraZeneca?
Which other products are in Fusion Pharmaceuticals' pipeline?
What was revealed in the Phase 2 TATCIST trial of FPI-2265?
Where is Fusion Pharmaceuticals headquartered?
What type of facility does Fusion operate for manufacturing?
Who are Fusion's strategic supply partners?
What financial terms were involved in AstraZeneca's acquisition of Fusion?
